Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Mar. 31, 2021
Current assets:
Cash and cash equivalents	$ 457,742	$ 674,493
Accounts receivable, net	18,910	3,570
Marketable securities	70,020	10,435
Inventories	6,737	2,611
Prepaid expenses and other current assets	20,795	13,536
Amount due from related party	550	0
Total current assets	574,754	704,645
Property and equipment, net	2,952	3,300
Operating lease right-of-use asset	8,405	9,655
Other assets	18,181	7,427
Total assets	604,292	725,027
Current liabilities:
Accounts payable	12,130	17,809
Accrued expenses and other current liabilities	58,423	44,612
Share-based compensation liabilities	2,724	21,636
Deferred revenue	100,564	100,564
Amounts due to Pfizer	37,727	1,954
Cost share advance from Pfizer	55,026	92,415
Operating lease liability	2,052	1,807
Amounts due to related parties	391	543
Total current liabilities	269,037	281,340
Deferred revenue, non-current	400,849	397,369
Cost share advance from Pfizer, non-current	0	29,447
Long-term operating lease liability	7,618	9,189
Long-term debt, less current maturities (related party)	358,700	358,700
Other liabilities	371	2,947
Total liabilities	1,036,575	1,078,992
Commitments and contingencies (Note 9)
Shareholders’ deficit:
Common shares, $0.000017727 par value, 564,111,242 shares authorized; 93,658,206 and 91,000,869 issued and outstanding at December 31, 2021 and March 31, 2021, respectively	2	2
Additional paid-in capital	777,844	709,466
Accumulated other comprehensive loss	(17,285)	(17,285)
Accumulated deficit	(1,192,844)	(1,046,148)
Total shareholders’ deficit	(432,283)	(353,965)
Total liabilities and shareholders’ deficit	$ 604,292	$ 725,027